Scientific Library
- Acute Coronary Syndrom
- ASCVD Prevention
- Bifurcation Stenting
- Cardio-Oncology
- Congestive Heart Failure
- DAPT Duration
- Drug Coated Balloon
- Fractional Flow Reserve
- IVUS Guidance
- Optical Coherence Tomography
- Pulmonary Hypertension
- Rotational Atherectomy
- Shear Stress
- Stenting Left Main
- Transcatheter Aortic Valve Replacement
- Percutaneous LAA Occlusion
- Mitral/Tricuspid Valvular Disease
- Other Relevant Articles
-
Biological Phenotypes of Heart Failure With Preserved Ejection FractionLewis GA, Schelbert EB, Miller CA et al. -
Critical Appraisal of Contemporary Clinical Endpoint Definitions in Coronary Intervention Trials: A Guidance DocumentE Spitzer, E McFadden, PW Serruys et al.
-
Relation of prior statin and anti-hypertensive use to severity of disease among patients hospitalized with COVID-19: Findings from the American Heart Association’s COVID-19 Cardiovascular Disease RegistryLB Daniels, JT Ren, K Kumar et al.
-
Impact of Oxidative Stress on the Heart and Vasculature: Part 2 of a 3-Part SeriesMünzel T, Camici GG, Kovacic JC et al.
-
The Aging Cardiovascular System: Understanding It at the Cellular and Clinical LevelsPaneni F, Diaz Cañestro C, Camici GG et al.
-
Comparison of a Novel Biodegradable Polymer Sirolimus-Eluting Stent With a Durable Polymer Everolimus-Eluting Stent 5-Year Outcomes of the Randomized BIOFLOW-II TrialT Lefèvre, M Haude, FJ Neumann et al.
-
Coronary Catheterization and Percutaneous Coronary Intervention in China: 10-Year Results From the China PEACE-Retrospective CathPCI StudyZheng X, Curtis JP, China PEACE Collaborative Grou
-
Optimal medical therapy improves clinical outcomes in patients undergoing revascularization with percutaneous coronary intervention or coronary artery bypass grafting: insights from the Synergy Between Percutaneous Coronary Intervention with TAXUS and Cardiac Surgery (SYNTAX) trial at the 5-year follow-upIqbal J, Zhang YJ, Serruys PW et al.
http://www.cbsmd.cn Contact us by cbs@cbsmd.cn
Copyright ⓒ CBSMD Nanjing China. All rights reserved.
